Martina Burlando, Ilaria Salvi, Andrea Paravisi, Emanuele Cozzani, Aurora Parodi
{"title":"伊谢珠单抗成功治疗重度广泛性脓疱性银屑病1例","authors":"Martina Burlando, Ilaria Salvi, Andrea Paravisi, Emanuele Cozzani, Aurora Parodi","doi":"10.1159/000526037","DOIUrl":null,"url":null,"abstract":"<p><p>Generalized pustular psoriasis (GPP) is a severe and potentially life-threatening type of psoriasis. We present the case of a patient with severe GPP, at first unsuccessfully treated with cyclosporine. We chose to treat the patient with ixekizumab, an anti-IL-17 antibody known for its rapid action in psoriasis vulgaris, that has also been reported as effective in GPP. The patient improved rapidly, with resolution of the active lesions after the first administration. The treatment has been continued for 2 years, with no adverse events and sustained disease control. Ixekizumab could be considered a safe and effective option in patients with GPP.</p>","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":" ","pages":"326-329"},"PeriodicalIF":0.8000,"publicationDate":"2022-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/42/9c/cde-0014-0326.PMC9710421.pdf","citationCount":"1","resultStr":"{\"title\":\"Severe Generalized Pustular Psoriasis Successfully Treated with Ixekizumab: A Case Report.\",\"authors\":\"Martina Burlando, Ilaria Salvi, Andrea Paravisi, Emanuele Cozzani, Aurora Parodi\",\"doi\":\"10.1159/000526037\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Generalized pustular psoriasis (GPP) is a severe and potentially life-threatening type of psoriasis. We present the case of a patient with severe GPP, at first unsuccessfully treated with cyclosporine. We chose to treat the patient with ixekizumab, an anti-IL-17 antibody known for its rapid action in psoriasis vulgaris, that has also been reported as effective in GPP. The patient improved rapidly, with resolution of the active lesions after the first administration. The treatment has been continued for 2 years, with no adverse events and sustained disease control. Ixekizumab could be considered a safe and effective option in patients with GPP.</p>\",\"PeriodicalId\":9619,\"journal\":{\"name\":\"Case Reports in Dermatology\",\"volume\":\" \",\"pages\":\"326-329\"},\"PeriodicalIF\":0.8000,\"publicationDate\":\"2022-11-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/42/9c/cde-0014-0326.PMC9710421.pdf\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Case Reports in Dermatology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1159/000526037\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/9/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Dermatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000526037","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/9/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"DERMATOLOGY","Score":null,"Total":0}
Severe Generalized Pustular Psoriasis Successfully Treated with Ixekizumab: A Case Report.
Generalized pustular psoriasis (GPP) is a severe and potentially life-threatening type of psoriasis. We present the case of a patient with severe GPP, at first unsuccessfully treated with cyclosporine. We chose to treat the patient with ixekizumab, an anti-IL-17 antibody known for its rapid action in psoriasis vulgaris, that has also been reported as effective in GPP. The patient improved rapidly, with resolution of the active lesions after the first administration. The treatment has been continued for 2 years, with no adverse events and sustained disease control. Ixekizumab could be considered a safe and effective option in patients with GPP.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
